This report for the first time identifies and profiles 480 Active Neurology focused Drug Development companies from 31 countries worldwide, developing 801 neurological disorders targeting drugs. It evaluates 16 major neurological indications drug development pipeline and analysis it to provide thousands of active clinical trials information; emerging drug targets, molecule types etc. Thus all together brings the most updated and robust information at the fingertips. It creates immense authentic knowledge-base (all information with references) on hundreds of proprietary technologies, M&A deals and partnering occurring in domain in last 10 years.

The 16 Major Indications detailed coverage in the report includes- Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Schizophrenia, Major Depressive Disorder, Amyotrophic Lateral Sclerosis, Ischemic and Hemorrhagic Stroke, Huntington’s Disease, Epilepsy, Pain (Migraine, Neurotropic and Post Hepatic Neuralgia), Neurological Trauma, Anxiety Disorders, ADHD, Addiction, Autism Spectrum Disorder, Bipolar Disorder and other Rare Neurological disorder.

Report covers each individual indication Epidemiology, Treatment options, Top selling drugs and their sales, indication Market size and forecast with detailed drug development Pipeline Analysis covering all Monoclonal Antibodies, Vaccines, Stem Cell Therapies, and Medical Devices in development, it also covers promising technologies and top drug development targets for the indication. Thus making it a versatile Comprehensive Report for Decision-Making.

A Single Innovative and Unique Report provide Answers to Many:

• It provides immense opportunities in identifying emerging cancer companies. It covers active 272 clinical, 208 Preclinical and Discovery stage companies along with their current partners, technologies and cancer drug pipeline.
• It provides LinkedIn and E-mail IDs of all decision makers in individual clinical companies. These thousand’s of focused links helps in saving time and linking to right person to further work on finer details.
• 16 Major Neurological Indication’s Individual Drug Development Pipeline and its Analysis, Market Size and Forecast.
• Rare Neurological Indications Drug development pipelines are also included, separately.
• All Finer Details are further elaborated in the individual 480 Companies Profiles, all written in form of mini reports.
• Offers complete and focused lead identification details for Biosuppliers /CROs.
• The complete 532 Pages report is highly interlinked with all Clinical Trials numbers and last updated status.
• The Text is supplemented with 98 Tables and 36 Figures/Info-graphics.

Foreword

List of Figures

List of Tables

List of Clinical Stage Companies

List of Preclinical Stage Companies

List of Discovery Stage Companies

Executive Summary

SECTION A – INFOGRAPHICS –WORLDWIDE NEUROLOGICAL DRUG DEVELOPERS

Worldwide Distribution of Companies with Active Neurological Disorders Drug Pipeline

Quantitative Estimation of Neurological Drug Developers present in U.S.A vs. Europe vs. Asia vs. Rest of the World. (480 Companies)

Quantitative Estimation of Clinical, exclusive Preclinical & Discovery companies present in U.S.A (263 Companies)

Quantitative Estimation of Clinical, exclusive Preclinical & Discovery companies present in Europe. (122 Companies)

Quantitative Estimation of Clinical, exclusive Preclinical & Discovery companies present in Asia. (69 Companies)

Country-wise Distribution of Companies (Clinical, Exclusive Preclinical & Discovery) having Active Neurological Disorders Drug Pipeline in Europe and Asia Region.

State-wise Distribution of Companies (Clinical, Exclusive Preclinical & Discovery) having Active Neurological Disorders Drug Pipeline in U.S.A.

Quantitative Estimation of Neurological Drug Developers on the basis of Human Resource Employed.

Top 10 Neurological Drug Developers with their total employees vs. total number of R&D staff for past three consecutive years.

Distribution of 480 companies, on the basis of year of establishment – to explore the emergence of R&D in Neurological Drug Discovery.

SECTION B – DEEP INSIGHTS –MARKET FORECAST AND PIPELINE ANALYSIS OF

16 MAJOR NEUROLOGICAL INDICATIONS

Active Drug Molecules in Development for various Neurological Indications – Info graphics

Quantitative Division of Active Drug Developmental Pipeline – Small Molecules vs Biologics (MAbs, Vaccines, Proteins etc.) (800 Molecules)

Distribution of Pipeline Molecules on the Basis of Developmental Stages – Clinical (Ph III/II/I) vs Preclinical vs. Discovery.

Quantitative Estimation of Clinical, exclusive Preclinical & Discovery companies present in Europe. (122 Companies)

ALZHIMER’S DISEASE –

Overview, Epidemiology, Treatment Options (Top Selling Drugs & their Annual Sales), Market Size & Forecast.

Detailed Pipeline Analysis (187 Active Molecules in Development) –

Small Molecules, Antibodies, Vaccines, Biologics (stem cells, peptides etc.) & Treatment Devices in Development; Top Drug Targets; Most Promising Technologies/Treatment Options in Development; Most Active Companies in Alzheimer’s Drug Development with their portfolio molecules.

Complete Drug Developmental Pipeline (Clinical/Preclinical/Discovery) with Drug Name, Developer & Target Details.

PARKINSON’S DISEASE –

Overview, Epidemiology, Treatment Options (Top Selling Drugs & their Annual Sales), Market Size & Forecast.

Detailed Pipeline Analysis (106 Active Molecules in Development) –

Small Molecules, Antibodies, Vaccines, Biologics (stem cells, peptides etc.) & Treatment Devices in Development; Top Drug Targets; Most Promising Technologies/Treatment Options in Development; Most Active Companies in Parkinson’s Drug Development with their portfolio molecules.

Complete Drug Developmental Pipeline (Clinical/Preclinical/Discovery) with Drug Name, Developer & Target Details.

MULTIPLE SCLEROSIS –

Overview, Epidemiology, Treatment Options (Top Selling Drugs & their Annual Sales), Market Size & Forecast.

Detailed Pipeline Analysis (86 Active Molecules in Development) –

Small Molecules, Antibodies, Vaccines, Biologics (stem cells, peptides etc.) & Treatment Devices in Development; Top Drug Targets; Most Promising Technologies/Treatment Options in Development; Most Active Companies for Multiple Sclerosis Drug Development with their portfolio molecules.

Complete Drug Developmental Pipeline (Clinical/Preclinical/Discovery) with Drug Name, Developer & Target Details.

SCHIZOPHRENIA –

Overview, Epidemiology, Treatment Options (Top Selling Drugs & their Annual Sales), Market Size & Forecast.

Detailed Pipeline Analysis – (53 Active Molecules in Development)

Small Molecules, Biologics (stem cells, peptides etc.) and Treatment Devices in Development; Top Drug Targets; Most Promising Technologies/ Treatment Options in Development; Most Active Companies in Schizophrenia Drug Development with their portfolio molecules.

Complete Drug Developmental Pipeline (Clinical/Preclinical/Discovery) with Drug Name, Developer & Target Details.

MAJOR DEPRESSIVE DISORDER (DEPRESSION) –

Overview, Epidemiology, Treatment Options (Top Selling Drugs & their Annual Sales), Market Size & Forecast.

Detailed Pipeline Analysis (61 Active Molecules) –

Small Molecules, Monoclonal Antibodies and Treatment Devices in Development; Top Drug Targets; Most Promising Technologies/Treatment Options in Development; Most Active Companies for Depression Drug Development with their portfolio molecules.

Complete Drug Developmental Pipeline (Clinical/Preclinical/Discovery) with Drug Name, Developer & Target Details.

AMYOTROPHIC LATERAL SCLEROSIS –

Overview, Epidemiology, Treatment Options (Top Selling Drugs & their Annual Sales), Market Size & Forecast.

Detailed Pipeline Analysis (41 Active Molecules in Development) –

Small Molecules, Monoclonal Antibodies and Biologics (stem cells, peptides etc.) in Development; Top Drug Targets; Most Promising Technologies/Treatment Options in Development; Most Active Companies in ALS Drug Development, with their portfolio molecules.

Complete Drug Developmental Pipeline (Clinical/Preclinical/Discovery) with Drug Name, Developer & Target Details.

ISCHEMIC & HEMORRHAGIC STROKE –

Overview, Epidemiology, Treatment Options (Top Selling Drugs & their Annual Sales), Market Size & Forecast.

Detailed Pipeline Analysis – (39 Active Molecules in Development)

Small Molecules, Biologics (stem cells, peptides etc.) and Treatment Devices in Development; Top Drug Targets; Most Promising Technologies/Treatment Options in Development; Most Active Companies in Stroke Drug Development, with their portfolio molecules.

Complete Drug Developmental Pipeline (Clinical/Preclinical/Discovery) with Drug Name, Developer & Target Details.

HUNTINGTON’S DISEASE –

Overview, Epidemiology, Treatment Options (Top Selling Drugs & their Annual Sales), Market Size & Forecast.

Detailed Pipeline Analysis – (38 Active Molecules in Development).

Small Molecules and Biologics (stem cells, peptides etc.) in Development; Top Drug Targets; Most Promising Technologies/Treatment Options in Development; Most Active Companies in Huntington’s Disease Drug Development, with their portfolio molecules.

Complete Drug Developmental Pipeline (Clinical/Preclinical/Discovery) with Drug Name, Developer & Target Details.

EPILEPSY –

Overview, Epidemiology, Treatment Options (Top Selling Drugs & their Annual Sales), Market Size & Forecast.

Detailed Pipeline Analysis – (32 Active Molecules in Development)

Small Molecules, Biologics (stem cells, peptides etc.) and Treatment Devices in Development; Top Drug Targets; Most Promising Technologies/Treatment Options in Development; Most Active Companies in Epilepsy Drug Development, with their portfolio molecules.

Complete Drug Developmental Pipeline (Clinical/Preclinical/Discovery) with Drug Name, Developer & Target Details.

PAIN (MIGRAINE, NEUROPATHIC & POST HEPATIC NEURALGIA) –

Overview, Epidemiology, Treatment Options (Top Selling Drugs & their Annual Sales), Market Size & Forecast.

Detailed Pipeline Analysis – (108 Active Molecules in Development)

Small Molecules, Monoclonal Antibodies, Biologics (stem cells, peptides etc.) & Treatment Devices in Development; Top Drug Targets; Most Promising Technologies/Treatment Options in Development; Most Active Companies in Pain Drug Development, with their portfolio molecules.

Complete Drug Developmental Pipeline (Clinical/Preclinical/Discovery) with Drug Name, Developer & Target Details.

NEUROTRAUMA (TRAUMATIC BRAIN INJURY & SPINAL CORD INJURY) –

Overview, Epidemiology, Treatment Options (Top Selling Drugs & their Annual Sales), Market Size & Forecast.

Detailed Pipeline Analysis (187 Active Molecules in Development) –

Small Molecules, Antibodies, Vaccines, Biologics (stem cells, peptides etc.) & Treatment Devices in Development; Top Drug Targets; Most Promising Technologies/Treatment Options in Development; Most Active Companies in Neurotrauma Drug Development with their portfolio molecules.

Complete Drug Developmental Pipeline (Clinical/Preclinical/Discovery) with Drug Name, Developer & Target Details.

ANXIETY (POST -TRAUMATIC STRESS DISORDER, PANIC & ANXIETY DISORDERS) –

Overview, Epidemiology, Treatment Options (Top Selling Drugs & their Annual Sales), Market Size & Forecast.

Pipeline Analysis (20 Active Molecules in Development) –

Complete Drug Developmental Pipeline (Clinical/Preclinical/Discovery) with Drug Name, Developer & Target Details.

ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) –

Overview, Epidemiology, Treatment Options (Top Selling Drugs & their Annual Sales), Market Size & Forecast.

Pipeline Analysis (20 Active Molecules in Development) –

Complete Drug Developmental Pipeline (Clinical/Preclinical/Discovery) with Drug Name, Developer & Target Details.

AUTISM SPECTRUM DISORDERS –

Overview, Epidemiology, Treatment Options (Top Selling Drugs & their Annual Sales), Market Size & Forecast.

Detailed Pipeline Analysis (13 Active Molecules in Development) –

Complete Drug Developmental Pipeline (Clinical/Preclinical/Discovery) with Drug Name, Developer & Target Details.

ADDICTION (ALCHOL / COCAINE DEPENDENCE & GENERAL ADDICTION)–

Overview, Epidemiology, Treatment Options (Top Selling Drugs & their Annual Sales), Market Size & Forecast.

Detailed Pipeline Analysis (10 Active Molecules in Development) –

Complete Drug Developmental Pipeline (Clinical/Preclinical/Discovery) with Drug Name, Developer & Target Details.

BIPOLAR DISORDER –

Overview, Epidemiology, Treatment Options (Top Selling Drugs & their Annual Sales), Market Size & Forecast.

Detailed Pipeline Analysis (10 Active Molecules in Development) –

Complete Drug Developmental Pipeline (Clinical/Preclinical/Discovery) with Drug Name, Developer & Target Details.

OTHER RARE NEUROLOGICAL INDICATION DRUG DEVELOPMENT PIPELINE –

Pipeline Analysis (65 Active Molecules in Development for various Rare Neurological Disorders) –

Complete Drug Developmental Pipeline (Clinical/Preclinical/Discovery) with Drug Name, Developer & Target Details.

SECTION C – INDIVIDUAL COMPANY PROFILE – CLINICAL PIPELINE

A to Z Alphabetical Profiles of Neurological Clinical Drug Development Companies (272 companies)

Individual Company Profile Page(s) Includes:

Company Profile – Key Technology Platform details, Neurology centered Deals, Collaborations and Business Insights; Key Investors and Key Partners.

Clinical / Preclinical / Discovery Pipeline Profile – Drug name, mechanism of Action, its target with current development status in neurological indications; Clinical Trial Number, current clinical trial status (Active, Re­cruiting, Completed etc); FDA/EMEA Orphan drug status, Special Protocol Assessment, fast track approvals etc.

Management Profile – Key Management (CXOs) details with email ID & LinkedIn ID, company address, contact phone number, employee number range, ownership and valuation status. Listed Stock Exchange and its tricker code & market capitalization (as on 2/5/2014).

SECTION D – INDIVIDUAL COMPANY PROFILE – PRE-CLINICAL PIPELINE

 A to Z Alphabetical Profiles of Neurological Pre-clinical Drug Development Companies (172 companies)

Individual Company Profile Page Includes:

Company Profile – Key Technology Platform details, Neurology centered Deals, Collaborations and Business Insights; Key Investors and Key Partners.

Preclinical / Discovery Pipeline Profile – Drug name, mechanism of Action, its target with current develop­ment status in neurological indications.

Management Profile – Key Management (CXOs) details, company address, contact phone number, employee number range, Ownership and valuation status. Listed Stock Exchange and its tricker code & market capitali­zation (as on 2/5/2014).

SECTION E – INDIVIDUAL COMPANY PROFILE – DISCOVERY PIPELINE

 A to Z Alphabetical Profiles of Neurological Discovery Drug Development Companies (36 companies)

Individual Company Profile Page Includes:

Company Profile – Key Technology Platform details, Neurology centered Deals, Collaborations and Business Insights; Key Investors and Key Partners.

Discovery Pipeline Profile – Drug name, Mechanism of Action, its target with current development status for neurological indications.

Management Profile – Key Management (CXOs) details, company address, contact phone number, employee number range, Ownership and valuation status. Listed Stock Exchange and its tricker code & market capitalization (as on 2/05/2014).

 Appendix A: List of Active Molecules in Development.

Appendix B: Country-wise List of Companies.

Appendix C: United States of America- State-wise List of Companies.

Table A.1 Top 10 Neurology Drug Development Companies, in terms of Employee Numbers, along-with their R&D employee numbers of past three years.

Table B.1 Top Selling Drugs, with their short description & recent sales figure for Alzheimer’s Disease.

Table B.2 List of Monoclonal Antibodies in development for the treatment of Alzheimer’s Disease. (14 Molecules)

Table B.3 List of Vaccines in development for the treatment of Alzheimer’s Disease. (16 Molecules)

Table B.4 List of other Biologics (stem cell/peptides/recombinants etc.) in development for the treatment of Alzheimer’s Disease. (26 Molecules)

Table B.5 List of Medical Devices in development for the treatment of Alzheimer’s Disease.

Table B.6 List of Top Drug Targets and their corresponding drugs in development for Alzheimer’s Disease.

Table B.7 Upcoming three most promising Technologies/Treatment options for Alzheimer’s Disease.

Table B.8 List of 8 most Active Companies and their Drugs in Development against Alzheimer’s Disease.

Table B.9 Complete Alzheimer’s Disease Drug Development Pipeline, with current development phase, target and developer’s name. (187 Molecules)

Table B.10 Top Selling Drugs, with their short description & recent sales figure for Parkinson’s Disease.  

Table B.11 List of Monoclonal Antibodies in development for the treatment of Parkinson’s Disease. (1 Molecule)

Table B.12 List of Vaccines in development for the treatment of Parkinson’s Disease. (1 Molecule)

Table B.13 List of other Biologics (stem cell/peptides/recombinants etc.) in development, for the treatment of Parkinson’s Disease. (24 Molecules)

Table B.14 List of Medical Devices in development for the treatment of Parkinson’s Disease.

Table B.15 List of Top Drug Targets and their corresponding drugs in development for Parkinson’s Disease.

Table B.16 Upcoming three most promising Technologies/Treatment options for Parkinson’s Disease.

Table B.17 List of 7 most Active Companies and their Drugs in Development against Parkinson’s Disease.

Table B.18 Complete Parkinson’s Disease Drug Development Pipeline, with current development phase, target and developer’s name. (187 Molecules)

Table B.19 Top Selling Drugs, with their short description & recent sales figure for Multiple Sclerosis.

Table B.20 List of Monoclonal Antibodies in development for the treatment of Multiple Sclerosis. (11 Molecule)

Table B.21 List of Vaccines in development for the treatment of Multiple Sclerosis. (4 Molecule)

Table B.22 List of other Biologics (stem cell/peptides/recombinants etc.) in development for the treatment of Multiple Sclerosis. (21 Molecules)

Table B.23 List of Medical Devices in development for the treatment of Multiple Sclerosis.

Table B.24 List of Top Drug Targets and their corresponding drugs in development for Multiple Sclerosis.

Table B.25 Upcoming three most promising Technologies/Treatment options for Multiple Sclerosis.

Table B.26 List of 8 most Active Companies and their Drugs in Development against Multiple Sclerosis.

Table B.27 Complete Multiple Sclerosis Drug Development Pipeline, with current development phase, target and developer’s name. (86 Molecules)

Table B.28 Top Selling Drugs, with their short description & recent sales figure for Schizophrenia.

Table B.29 List of other Biologics (stem cell/peptides/recombinants etc.) in development for the treatment of Schizophrenia. (1 Molecules)

Table B.30 List of Medical Devices in development for the treatment of Schizophrenia.

Table B.31 List of Top Drug Targets and their corresponding drugs in development for Schizophrenia.

Table B.32 Upcoming three most promising Technologies/Treatment options for Schizophrenia.

Table B.33 List of 8 most Active Companies and their Drugs in De velopment against Schizophrenia.

Table B.34 Complete Schizophrenia Drug Development Pipeline, with current development phase, target and developer’s name. (53 Molecules)

Table B.35 Top Selling Drugs, with their short description & recent sales figure for Major Depressive Disorder.

Table B.36 List of Monoclonal Antibodies in development for the treatment of Major Depressive Disorder. (2 Molecules)

Table B.37 List of Medical Devices in development for the treatment of Major Depressive Disorder.

Table B.38 List of Top Drug Targets and their corresponding drugs in development for Major Depressive Disorder.

Table B.39 Upcoming three most promising Technologies/Treatment options for Major Depressive Disorder.

Table B.40 List of 9 most Active Companies and their Drugs in De velopment against Major Depressive Disorder.

Table B.41 Complete Major Depressive Disorder Drug Development Pipeline, with current development phase, target and developer’s name. (61 Molecules)

Table B.42 Top Selling Drugs, with their short description & recent sales figure for Amyotrophic Lateral Sclerosis.

Table B.43 List of Monoclonal Antibodies in development for the treatment of Amyotrophic Lateral Sclerosis. (2 Molecules)

Table B.44 List of other Biologics (stem cell/peptides/recombinants etc.) in development for the treatment of Amyotrophic Lateral Sclerosis. (18 Molecules)

Table B.45 List of Top Drug Targets and their corresponding drugs in development for Amyotrophic Lateral Sclerosis.

Table B.46 Upcoming three most promising Technologies/Treatment options for Amyotrophic Lateral Sclerosis.

Table B.47 List of 2 most Active Companies and their Drugs in De velopment against Amyotrophic Lateral Sclerosis.

Table B.48 Complete Amyotrophic Lateral Sclerosis Drug Development Pipeline, with current development phase, target and developer’s name. (41 Molecules)

Table B.49 Top Selling Drugs, with their short description & recent sales figure for Ischemic & Hemorrhagic Stroke.

Table B.50 List of other Biologics (stem cell/peptides/recombinants etc.) in development for the treatment of Ischemic & Hemorrhagic Stroke. (17 Molecules)

Table B.51 List of Medical Devices in development for the treatment of Ischemic & Hemorrhagic Stroke.

Table B.52 List of Top Drug Targets and their corresponding drugs in development for Ischemic & Hemorrhagic Stroke.

Table B.53 Upcoming three most promising Technologies/Treatment options for Ischemic & Hemorrhagic Stroke.

Table B.54 List of most Active Companies and their Drugs in De velopment against Ischemic & Hemorrhagic Stroke.

Table B.55 Complete Ischemic & hemorrhagic Stroke Development Pipeline, with current development phase, target and developer’s name. (39 Molecules)

Table B.56 Top Selling Drugs, with their short description & recent sales figure for Huntington’s Disease.

Table B.57 List of other Biologics (stem cell/peptides/recombinants etc.) in development for the treatment of Huntington’s Disease. (9 Molecules)

Table B.58 List of Top Drug Targets and their corresponding drugs in development for Huntington’s Disease.

Table B.59 Upcoming three most promising Technologies/Treatment options for Huntington’s Disease.

Table B.60 List of 2 most Active Companies and their Drugs in De velopment against Huntington’s Disease.

Table B.61 Complete Huntington’s Disease Drug Development Pipeline, with current development phase, target and developer’s name. (38 Molecules)

Table B.62 Top Selling Drugs, with their short description & recent sales figure for Epilepsy.

Table B.63 List of other Biologics (stem cell/peptides/recombinants etc.) in development for the treatment of Epilepsy. Table B.64 List of Medical Devices in development for the treatment of Epilepsy.

Table B.65 List of Top Drug Targets and their corresponding drugs in development for the treatment of Epilepsy.

Table B.66 Upcoming three most promising Technologies/Treatment options for Epilepsy.

Table B.67 List of 3 most Active Companies and their Drugs in De velopment against Epilepsy.

Table B.68 Complete Epilepsy Disease Drug Development Pipeline, with current development phase, target and developer’s name. (32 Molecules)

Table B.69 Top Selling Drugs, with their short description & recent sales figure in Pain (Migraine, Neuropathic, Post hepatic Neuralgia) .

Table B.70 List of Monoclonal Antibodies in development for the treatment of Pain. (3 Molecules)

Table B.71 List of Biologics (stem cell/peptides/recombinants etc.) in development for the treatment of Pain. (11 Molecules)

Table B.72 List of Medical Devices in development for the treatment of Pain.

Table B.73 List of Top Drug Targets and their corresponding drugs in development for Pain.

Table B.74 Upcoming three most promising Technologies/Treatment options for Pain.

Table B.75 List of 8 most Active Companies and their Drugs in De velopment against Pain.

Table B.76 Complete Migraine Drug Development Pipeline, with current development phase, target and developer’s name. (23 Molecules)

Table B.77 Complete Neuropathic Pain Drug Development Pipeline, with current development phase, target and de­veloper’s name. (69 Molecules)

Table B.78 Complete Post Hepatic Neuralgia Drug Development Pipeline, with current development phase, target and developer’s name. (16 Molecules)

Table B.79 Top Selling Drugs, with their short description & recent sales figure for Neurological Trauma.

Table B.80 List of Monoclonal Antibodies in development for the treatment of Neurological Trauma. (1 Molecules)

Table B.81 List of Biologics (stem cell/peptides/recombinants etc.) in development for the treatment of Neurological Trauma. (19 Molecules)

Table B.82 List of Medical Devices in development for the treatment of Neurological Trauma.

Table B.83 List of Top Drug Targets and their corresponding drugs in development for Neurological Trauma.

Table B.84 Upcoming three most promising Technologies/Treatment options for Neurological Trauma.

Table B.85 List of 4 most Active Companies and their Drugs in De velopment against Neurological Trauma.

Table B.86 Complete Traumatic Brain Injury Drug Development Pipeline, with current development phase, target and developer’s name. (23 Molecules)

Table B.87 Complete Spinal Cord Injury Drug Development Pipeline, with current development phase, target and developer’s name. (23 Molecules)

Table B.88 Top Selling Drugs, with their short description & recent sales figure for Anxiety.

Table B.89 Complete Anxiety Drug Development Pipeline, with current development phase, target and developer’s name. (20 Molecules)

Table B.90 Top Selling Drugs, with their short description & recent sales figure for Attention Deficit Hyperactivity Disor­der (ADHD).

Table B.91 Complete Attention Deficit Hyperactivity Disorder Drug Development Pipeline, with current development phase, target and developer’s name. (20 Molecules)

Table B.92 Top Selling Drugs, with their short description & recent sales figure for Autism Spectrum Disorder.

Table B.93 Complete Autism Spectrum Disorder Drug Development Pipeline, with current development phase, target and developer’s name. (13 Molecules)

Table B.94 Top Selling Drugs, with their short description & recent sales figure for Addiction.

Table B.95 Complete Addiction Drug Development Pipeline, with current development phase, target and developer’s name. (10 Molecules)

Table B.96 Top Selling Drugs, with their short description & recent sales figure for Bipolar Disorder.

Table B.97 Complete Bipolar Disorder Drug Development Pipeline, with current development phase, target and developer’s name. (10 Molecules)

Table B.98 Other Rare Neurological Disorder Drug Development.

Figure A.1  Quantitative Estimation of Neurological Drug Developers present in U.S.A vs Europe vs. Asia vs. Rest of the World. (480 Companies)

Figure A.2  Quantitative Estimation of Clinical, exclusive Preclinical & Discovery companies present in U.S.A. (263 Companies)

Figure A.3  Quantitative Estimation of Clinical, exclusive Preclinical & Discovery companies present in Europe. (122 Companies)

Figure A.4 Quantitative Estimation of Clinical, exclusive Preclinical & Discovery companies present in Asia. (69 Companies)

Figure A.5 Showing all Individual 19 Countries in Europe and 8 Countries in Asia, along with the individual number of Neuro focused Drug Developers present in the countries.

Figure A.6 Bar Graph for Country-wise Distribution of Companies (Clinical, Preclinical & Discovery) having Active Neurological Disorders Drug Pipeline in Europe Region.

Figure A.7 Bar Graph for Country-wise Distribution of Companies (Clinical, Preclinical & Discovery) having Active Neuro­logical Disorders Drug Pipeline in Asia Region.

Figure A.8 Showing all Individual 28 States in America, along with the individual number of Neuro focused Drug Developers present in these States.

Figure A.9 Bar Graph for State-wise Distribution of Companies (Clinical, Preclinical & Discovery) in U.S.A, with Active

Neurology Drug Developmental Pipeline.

Figure A.10 Quantitate Estimation of Neurological Drug Developers on the basis of Human Resource Employed.

Figure A.11 Distribution of 480 Neuro Drug Developers on the basis of Year of Establishment- to explore the emergence of R&D in Neurological Drug Discovery.

Figure A.12 Bar Graph to reflect year-wise Incorporation pattern of Neuro Drug Developers, from 1991 onwards.

Figure B.1  Drugs in Development for the treatment of various Neurological Disorder –

1. Division of Molecules among Small, Monoclonal Antibodies, Vaccines & other Biologics.
2. Division of Molecules on the basis of its highest developmental stage – Clinical , Pre-clinical & Discovery.

Figure B.2  Geographic Distribution of Drugs in Development for the treatment of various Neurological Disorders.

1. Geographic distribution of molecules among USA, Europe, Asia and Rest of the World.
2. Development Stage-wise (Clinical, PreClinical & Discovery) division of molecules among USA, Europe, Asia & ROW.

Figure B.3  Neurological Drugs Indications in various Development Stages (Clinical, Preclinical & Discovery).

Figure B.4  Geographic Distribution of Drugs in Development for the treatment of various Neurological Disorders.

1. Geographic distribution of molecules among USA, Europe, Asia and Rest of the World.
2. Development Stage-wise (Clinical, PreClinical & Discovery) division of molecules among USA, Europe, Asia & ROW.

Figure B.5  Quantitative estimation of companies with active Alzheimer’s drug development program vs. others.

Figure B.6  Pipeline Analysis- Alzheimer’s drug development pipeline distribution –

1. Molecule Type (small molecules vs. biologics vs. others).
2. Development Stage-wise – clinical (PhIII/PhII/PhI), preclinical vs. discovery.

Figure B.7  Quantitative estimation of companies with active Parkinson’s drug development program vs. others.

Figure B.8  Pipeline Analysis – Parkinson’s drug development pipeline distribution –

1. Molecule Type (small molecules vs. biologics vs. others).
2. Development Stage-wise – clinical (PhIII/PhII/PhI), preclinical vs. discovery.

Figure B.9  Quantitative estimation of companies with active Multiple Sclerosis drug development program vs. others.

Figure B.10  Pipeline Analysis – Multiple Sclerosis drug development pipeline distribution –

1. Molecule Type (small molecules vs. biologics vs. others).
2. Development Stage-wise – clinical (PhIII/PhII/PhI), preclinical vs. discovery.

Figure B.11  Quantitative estimation of companies with active Schizophrenia drug development program vs. others.

Figure B.12  Pipeline Analysis – Schizophrenia drug development pipeline distribution –

1. Molecule Type (small molecules vs. biologics vs. others).
2. Development Stage-wise – clinical (PhIII/PhII/PhI), preclinical vs. discovery.

Figure B.13  Quantitative estimation of companies with active Depression drug development program vs. others.

Figure B.14  Pipeline Analysis – Major Depressive Disorder drug development pipeline distribution –

1. Molecule Type (small molecules vs. biologics vs. others).
2. Development Stage-wise – clinical (PhIII/PhII/PhI), preclinical vs. discovery.

Figure B.15  Quantitative estimation of companies with active Amyotrophic Lateral Sclerosis drug development program vs. others

Figure B.16  Pipeline Analysis – Amyotrophic Lateral Sclerosis drug development pipeline distribution –

1. Molecule Type (small molecules vs. biologics vs. others).
2. Development Stage-wise – clinical (PhIII/PhII/PhI), preclinical vs. discovery.

Figure B.17  Quantitative estimation of companies with active Stroke drug development program vs. others.

Figure B.18  Pipeline Analysis – Ischemic & Hemorrhagic Stroke drug development pipeline distribution –

1. Molecule Type (small molecules vs. biologics vs. others).
2. Development Stage-wise – clinical (PhIII/PhII/PhI), preclinical vs. discovery.

Figure B.19  Quantitative estimation of companies with active Huntington’s drug development program vs. others.

Figure B.20  Pipeline Analysis – Huntington’s drug development pipeline distribution –

1. Molecule Type (small molecules vs. biologics vs. others).
2. Development Stage-wise – clinical (PhIII/PhII/PhI), preclinical vs. discovery.

Figure B.21  Quantitative estimation of companies with active Epilepsy drug development program vs. others.

Figure B.22  Pipeline Analysis – Epilepsy drug development pipeline distribution-

1. Molecule Type (small molecules vs. biologics vs. others).
2. Development Stage-wise – clinical (PhIII/PhII/PhI), preclinical vs. discovery.

Figure B.23  Quantitative estimation of companies with active Pain drug development program vs. others.

Figure B.24  Pipeline Analysis –Pain (Migraine, Neuropathic & Post Hepatic Neuralgia) drug development pipeline distribution-

1. Molecule Type (small molecules vs. biologics vs. others).
2. Development Stage-wise – clinical (PhIII/PhII/PhI), preclinical vs. discovery.

Figure B.25  Quantitative estimation of companies with active Neurotrauma drug development program vs. others.

Figure B.26  Pipeline Analysis –Neurotrauma(Traumatic Brain Injury & Spinal Cord Injury) drug development pipeline distribution-

1. Molecule Type (small molecules vs. biologics vs. others).
2. Development Stage-wise – clinical (PhIII/PhII/PhI), preclinical vs. discovery.

Figure B.27  Quantitative estimation of companies with active Anxiety drug development program vs. others.

Figure B.28  Pipeline Analysis –Anxiety (includes Post Traumatic Stress Disorder) drug development pipeline distribution-

1. Molecule Type (small molecules vs. biologics vs. others).
2. Development Stage-wise – clinical (PhIII/PhII/PhI), preclinical vs. discovery.

Figure B.29  Quantitative estimation of companies with active ADHD drug development program vs. others.

Figure B.30  Pipeline Analysis –Attention Deficit Hyperactivity Disorder (ADHD) drug development pipeline distribution –

1. Molecule Type (small molecules vs. biologics vs. others).
2. Development Stage-wise – clinical (PhIII/PhII/PhI), preclinical vs. discovery.

Figure B.31  Quantitative estimation of companies with active Autism Spectrum Disorders drug development program vs. others.

Figure B.32  Pipeline Analysis – Autism Spectrum Disorders drug development pipeline distribution –

1. Molecule Type (small molecules vs. biologics vs. others).
2. Development Stage-wise – clinical (PhIII/PhII/PhI), preclinical vs. discovery.

Figure B.33  Quantitative estimation of companies with active Addiction drug development program vs. others.

Figure B.34  Pipeline Analysis – Addiction (Alcohol/Cocaine & General Addiction) drug development pipeline distribution-

1. Molecule Type (small molecules vs. biologics vs. others).
2. Development Stage-wise – clinical (PhIII/PhII/PhI), preclinical vs. discovery.

Figure B.35  Quantitative estimation of companies with active Bipolar Disorder drug development program vs. others.

Figure B.36  Pipeline Analysis – Bipolar Disorder drug development pipeline distribution –

1. Molecule Type (small molecules vs. biologics vs. others).
2. Development Stage-wise – clinical (PhIII/PhII/PhI), preclinical vs. discovery.